首页 > 最新文献

Archives of rheumatology最新文献

英文 中文
Effects of acute aerobic exercise on brain-derived neurotrophic factor level in rheumatoid arthritis patients. 急性有氧运动对类风湿关节炎患者脑源性神经营养因子水平的影响
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9599
Songül Bağlan Yentur, Zübeyde Ercan, Gülnihal Deniz, Ahmet Karataş, Mustafa Gür, Gökhan Alkan, Süleyman Serdar Koca

Objectives: The study aimed to investigate the variation of brain-derived neurotrophic factor (BDNF) levels following acute exercise in patients with rheumatoid arthritis (RA).

Patients and methods: This cross-sectional study was conducted with 88 participants (25 males, 63 females; mean age: 45.1±8.3 years; range, 18 to 65 years) between July 2020 and May 2021. Of the participants, 44 were RA patients, and 44 were age-and sex-matched healthy controls. Aerobic exercise was utilized in all participants for a single session. Depression and anxiety levels were evaluated with the Beck Depression Inventory and Hospital Anxiety and Depression Scale. Blood samples were collected from all subjects before and immediately after the intervention.

Results: Serum BDNF levels (both baseline and after exercise) were similar in the RA and control groups. Although serum BDNF levels significantly decreased in both groups after aerobic exercise (Wilcoxon rank p<0.05), ΔBDNF levels were significantly higher in the RA group than in the control group (p=0.047). Additionally, ΔBDNF levels were significantly correlated with the Hospital Anxiety and Depression Scale scores in the RA group (p<0.05) but not in the control group.

Conclusion: A single bout of exercise may effectively decrease serum BDNF levels in patients with RA and healthy subjects. The long-term effect of exercise on BDNF levels should be investigated in prospective studies.

目的:研究类风湿关节炎(RA)患者急性运动后脑源性神经营养因子(BDNF)水平的变化。患者和方法:本横断面研究共纳入88名参与者(25名男性,63名女性;平均年龄:45.1±8.3岁;从2020年7月到2021年5月。在参与者中,44人是类风湿性关节炎患者,44人是年龄和性别匹配的健康对照。所有参与者都进行了一次有氧运动。采用贝克抑郁量表和医院焦虑抑郁量表评估抑郁和焦虑水平。在干预前和干预后立即采集所有受试者的血液样本。结果:RA组和对照组的血清BDNF水平(基线和运动后)相似。结论:单次运动可有效降低RA患者和健康受试者的血清BDNF水平。运动对BDNF水平的长期影响应在前瞻性研究中进行调查。
{"title":"Effects of acute aerobic exercise on brain-derived neurotrophic factor level in rheumatoid arthritis patients.","authors":"Songül Bağlan Yentur,&nbsp;Zübeyde Ercan,&nbsp;Gülnihal Deniz,&nbsp;Ahmet Karataş,&nbsp;Mustafa Gür,&nbsp;Gökhan Alkan,&nbsp;Süleyman Serdar Koca","doi":"10.46497/ArchRheumatol.2023.9599","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9599","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to investigate the variation of brain-derived neurotrophic factor (BDNF) levels following acute exercise in patients with rheumatoid arthritis (RA).</p><p><strong>Patients and methods: </strong>This cross-sectional study was conducted with 88 participants (25 males, 63 females; mean age: 45.1±8.3 years; range, 18 to 65 years) between July 2020 and May 2021. Of the participants, 44 were RA patients, and 44 were age-and sex-matched healthy controls. Aerobic exercise was utilized in all participants for a single session. Depression and anxiety levels were evaluated with the Beck Depression Inventory and Hospital Anxiety and Depression Scale. Blood samples were collected from all subjects before and immediately after the intervention.</p><p><strong>Results: </strong>Serum BDNF levels (both baseline and after exercise) were similar in the RA and control groups. Although serum BDNF levels significantly decreased in both groups after aerobic exercise (Wilcoxon rank p<0.05), ΔBDNF levels were significantly higher in the RA group than in the control group (p=0.047). Additionally, ΔBDNF levels were significantly correlated with the Hospital Anxiety and Depression Scale scores in the RA group (p<0.05) but not in the control group.</p><p><strong>Conclusion: </strong>A single bout of exercise may effectively decrease serum BDNF levels in patients with RA and healthy subjects. The long-term effect of exercise on BDNF levels should be investigated in prospective studies.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/c6/ArchRheumatol-2023-38-209.PMC10481692.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10245649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of risk factors for the progression and prognosis of connective tissue disease-associated interstitial lung disease. 结缔组织病相关间质性肺疾病进展及预后的危险因素分析
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9602
Ting Zhao, Fu-An Lin, Hongpu Chen

Objectives: This study aimed to investigate the risk factors of lung progression in patients with connective tissue disease-associated interstitial lung disease (ILD).

Patients and methods: A total of 91 ILD patients (28 males, 63 females; mean age: 54.9±11.3 years; range, 30 to 77 years) were included in the prospective follow-up study conducted throughout 2020. They were divided into progressors (n=27) and nonprogressors (n=64) according to whether the pulmonary disease progressed during a six-month follow-up period. The clinical data of the two groups were analyzed, and a logistic regression model was constructed to analyze the risk factors of the progression of ILD in all patients.

Results: Univariate analysis revealed significant differences (p<0.05) between the two groups in smoking history, serum ferritin, FVC% (the percentage of forced vital capacity), DLCO% (the percentage of diffusion capacity for carbon monoxide), and computed tomography involvement range. Further application of a logistic regression model revealed that increased serum ferritin level was an independent risk factor for ILD progression (odds ratio=1.002, 95% confidence interval: 1.000-1.003, p=0.004). The optimal critical value of serum ferritin was 303.25 ng/mL, the sensitivity and specificity were 81.5% and 54.7%, respectively, and the area under the curve was 0.747.

Conclusion: The level of serum ferritin may be an independent predictor for ILD progression.

目的:本研究旨在探讨结缔组织病相关间质性肺疾病(ILD)患者肺部进展的危险因素。患者和方法:91例ILD患者(男性28例,女性63例;平均年龄:54.9±11.3岁;范围,30至77岁)纳入了2020年进行的前瞻性随访研究。根据在6个月的随访期间肺部疾病是否进展,将他们分为进展者(n=27)和非进展者(n=64)。分析两组患者的临床资料,构建logistic回归模型,分析所有患者ILD进展的危险因素。结论:血清铁蛋白水平可能是ILD进展的独立预测因子。
{"title":"Analysis of risk factors for the progression and prognosis of connective tissue disease-associated interstitial lung disease.","authors":"Ting Zhao,&nbsp;Fu-An Lin,&nbsp;Hongpu Chen","doi":"10.46497/ArchRheumatol.2023.9602","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9602","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the risk factors of lung progression in patients with connective tissue disease-associated interstitial lung disease (ILD).</p><p><strong>Patients and methods: </strong>A total of 91 ILD patients (28 males, 63 females; mean age: 54.9±11.3 years; range, 30 to 77 years) were included in the prospective follow-up study conducted throughout 2020. They were divided into progressors (n=27) and nonprogressors (n=64) according to whether the pulmonary disease progressed during a six-month follow-up period. The clinical data of the two groups were analyzed, and a logistic regression model was constructed to analyze the risk factors of the progression of ILD in all patients.</p><p><strong>Results: </strong>Univariate analysis revealed significant differences (p<0.05) between the two groups in smoking history, serum ferritin, FVC% (the percentage of forced vital capacity), DLCO% (the percentage of diffusion capacity for carbon monoxide), and computed tomography involvement range. Further application of a logistic regression model revealed that increased serum ferritin level was an independent risk factor for ILD progression (odds ratio=1.002, 95% confidence interval: 1.000-1.003, p=0.004). The optimal critical value of serum ferritin was 303.25 ng/mL, the sensitivity and specificity were 81.5% and 54.7%, respectively, and the area under the curve was 0.747.</p><p><strong>Conclusion: </strong>The level of serum ferritin may be an independent predictor for ILD progression.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/25/ArchRheumatol-2023-38-274.PMC10481697.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ABCs of antiphospholipid syndrome. 抗磷脂综合征的abc。
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.41875
Ayşe Bahar Keleşoğlu Dinçer, Doruk Erkan

Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent antiphospholipid antibodies (aPL), namely anticardiolipin antibody (aCL), anti-β2 glycoprotein-I antibody (aβ2GPI), and lupus anticoagulant (LA). The diagnosis of APS requires careful assessment of the aPL profile, the clinical phenotype, and additional risk factors. The standard management of aPL-related thrombosis is anticoagulation, which is not effective for microvascular and non-thrombotic events. In parallel to our improved understanding of aPL-related mechanisms, the role of immunosuppression has been increasingly investigated. In this review, we summarize the basic concepts and future perspectives in APS.

抗磷脂综合征(APS)是一种以持续抗磷脂抗体(aPL)为特征的血栓性、微血管性、产科性或非血栓性事件为特征的血栓炎性综合征,即抗心磷脂抗体(aCL)、抗β2糖蛋白- 1抗体(aβ 2gpi)和狼疮抗凝剂(LA)。APS的诊断需要仔细评估aPL谱、临床表型和其他危险因素。apl相关血栓形成的标准处理是抗凝,对微血管和非血栓性事件无效。随着我们对apl相关机制的理解的提高,免疫抑制的作用也得到了越来越多的研究。本文综述了APS的基本概念和未来发展趋势。
{"title":"The ABCs of antiphospholipid syndrome.","authors":"Ayşe Bahar Keleşoğlu Dinçer,&nbsp;Doruk Erkan","doi":"10.46497/ArchRheumatol.2023.41875","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.41875","url":null,"abstract":"<p><p>Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent antiphospholipid antibodies (aPL), namely anticardiolipin antibody (aCL), anti-β2 glycoprotein-I antibody (aβ2GPI), and lupus anticoagulant (LA). The diagnosis of APS requires careful assessment of the aPL profile, the clinical phenotype, and additional risk factors. The standard management of aPL-related thrombosis is anticoagulation, which is not effective for microvascular and non-thrombotic events. In parallel to our improved understanding of aPL-related mechanisms, the role of immunosuppression has been increasingly investigated. In this review, we summarize the basic concepts and future perspectives in APS.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/25/ArchRheumatol-2023-38-163.PMC10481699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How can you examine intersection syndrome via ultrasound? A technical description. 如何通过超声检查交叉综合征?技术描述。
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9830
Esra Giray, Aslinur Keles Ercisli, Özge Gülsüm İlleez, İlknur Aktaş, İlker Yağcı
{"title":"How can you examine intersection syndrome via ultrasound? A technical description.","authors":"Esra Giray,&nbsp;Aslinur Keles Ercisli,&nbsp;Özge Gülsüm İlleez,&nbsp;İlknur Aktaş,&nbsp;İlker Yağcı","doi":"10.46497/ArchRheumatol.2023.9830","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9830","url":null,"abstract":"","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/67/ArchRheumatol-2023-38-324.PMC10481683.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10245646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Readmission reasons of pediatric patients diagnosed with multisystem inflammatory syndrome after discharge. 多系统炎症综合征患儿出院后再入院原因分析。
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9605
Ela Cem, Elif Kıymet, Elif Böncüoğlu, Şahika Şahinkaya, Miray Yılmaz Çelebi, Mustafa Gülderen, Aybüke Akaslan Kara, Timur Meşe, Hasan Ağin, Nuri Bayram, İlker Devrim

Objectives: There is no clear information in the literature about causes of reactivation of multisystem inflammatory syndrome in children (MIS-C) or indications for readmissions for MIS-C after discharge; as a result, the conditions that may develop after infection in children with MIS-C were discussed, and the reasons for hospitalization were screened.

Patients and methods: This single-center retrospective study was conducted with 95 patients (65 males, 30 females; mean age: 92.8±55.5 months; range, 5 to 17 months) between November 11, 2020, and December 30, 2021. Children who were rehospitalized in the study center after their discharge with the diagnosis of MIS-C were included in the study, and the indications for readmissions were evaluated.

Results: During the study period, six (6.3%) patients (4 males, 2 females; median age: 114.5 months [interquartile range: 122 months]) had to be rehospitalized. Four of these patients had an underlying disease, while the other two were previously healthy children. Fever was the most common reason for readmissions in half of the patients, while the remaining patients were readmitted with the indications of myocarditis, pneumonia, and posttraumatic pain syndrome.

Conclusion: Although no evidence for the reactivation of MIS-C was detected in patients in the literature, it should also be emphasized that close follow-up of these patients is a must, considering possible cardiac complications.

目的:文献中没有关于儿童多系统炎症综合征(MIS-C)再激活的原因或出院后MIS-C再入院的指征的明确信息;因此,讨论了misc儿童感染后可能出现的情况,并筛选了住院的原因。患者和方法:本单中心回顾性研究纳入95例患者(男性65例,女性30例;平均年龄:92.8±55.5个月;从2020年11月11日到2021年12月30日,期间为5至17个月。出院后在研究中心再次住院诊断为misc的儿童纳入研究,并评估再入院指征。结果:研究期间,6例(6.3%)患者(男4例,女2例;中位年龄:114.5个月[四分位数间距:122个月])不得不再次住院。其中四名患者有潜在疾病,而另外两名患者以前是健康儿童。发烧是一半患者再入院的最常见原因,而其余患者因心肌炎,肺炎和创伤后疼痛综合征的适应症再入院。结论:虽然在文献中没有发现MIS-C再激活的证据,但考虑到可能出现的心脏并发症,我们也应该强调对这些患者的密切随访是必须的。
{"title":"Readmission reasons of pediatric patients diagnosed with multisystem inflammatory syndrome after discharge.","authors":"Ela Cem,&nbsp;Elif Kıymet,&nbsp;Elif Böncüoğlu,&nbsp;Şahika Şahinkaya,&nbsp;Miray Yılmaz Çelebi,&nbsp;Mustafa Gülderen,&nbsp;Aybüke Akaslan Kara,&nbsp;Timur Meşe,&nbsp;Hasan Ağin,&nbsp;Nuri Bayram,&nbsp;İlker Devrim","doi":"10.46497/ArchRheumatol.2023.9605","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9605","url":null,"abstract":"<p><strong>Objectives: </strong>There is no clear information in the literature about causes of reactivation of multisystem inflammatory syndrome in children (MIS-C) or indications for readmissions for MIS-C after discharge; as a result, the conditions that may develop after infection in children with MIS-C were discussed, and the reasons for hospitalization were screened.</p><p><strong>Patients and methods: </strong>This single-center retrospective study was conducted with 95 patients (65 males, 30 females; mean age: 92.8±55.5 months; range, 5 to 17 months) between November 11, 2020, and December 30, 2021. Children who were rehospitalized in the study center after their discharge with the diagnosis of MIS-C were included in the study, and the indications for readmissions were evaluated.</p><p><strong>Results: </strong>During the study period, six (6.3%) patients (4 males, 2 females; median age: 114.5 months [interquartile range: 122 months]) had to be rehospitalized. Four of these patients had an underlying disease, while the other two were previously healthy children. Fever was the most common reason for readmissions in half of the patients, while the remaining patients were readmitted with the indications of myocarditis, pneumonia, and posttraumatic pain syndrome.</p><p><strong>Conclusion: </strong>Although no evidence for the reactivation of MIS-C was detected in patients in the literature, it should also be emphasized that close follow-up of these patients is a must, considering possible cardiac complications.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/3c/ArchRheumatol-2023-38-315.PMC10481694.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10187679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of a targeted next-generation sequencing-based genetic screening panel in patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome. 针对周期性发热、口疮性口炎、咽炎和腺炎综合征患者的下一代基于测序的基因筛查小组的应用
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9681
Rabia Miray Kışla Ekinci, Özlem Anlaş, Özge Özalp

Objectives: This study aims to investigate a genetic panel in patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome and examine its performance for an accurate differential diagnosis.

Patients and methods: Between January 2021 and January 2022, a total of 104 children with PFAPA syndrome (63 males, 41 females; mean age: 4.8±2.3 years; range, 1.2 to 8.9 years) were retrospectively analyzed. Next-generation sequencing test was performed using a custom QIAGEN- QIAseq™ Targeted DNA Panel which includes six genes namely ELANE, LPIN2, MEFV, MVK, NLRP3, and TNFRSF1A.

Results: Of 104 patients, 38 (36.5%) had variants in the genetic panel. The most common variants were found in the MEFV gene (n=35, 33.6%), the most frequent genotype was E148Q heterozygosity (n=16). Four and two patients were eventually diagnosed with Familial Mediterranean fever (FMF) and hyperimmunoglobulin D syndrome (HIDS), since they had confirmative biallelic pathogenic in the MEFV and MVK genes, respectively.

Conclusion: A genetic panel, including MEFV and MVK genes, may be useful in patients, clinically resembling PFAPA, since they may have HIDS or FMF, but lack typical features of the exact disease. Nonetheless, we believe that distinct genetic panels should be developed for different populations.

目的:本研究旨在研究周期性发热、口疮性口炎、咽炎和腺炎(PFAPA)综合征患者的基因面板,并检查其表现以进行准确的鉴别诊断。患者和方法:2021年1月至2022年1月,共104例PFAPA综合征患儿(男63例,女41例;平均年龄:4.8±2.3岁;年龄范围为1.2 - 8.9岁)。使用定制的QIAGEN- QIAseq™靶向DNA面板进行下一代测序测试,该面板包括6个基因,即ELANE, LPIN2, MEFV, MVK, NLRP3和TNFRSF1A。结果:104例患者中,38例(36.5%)存在遗传变异。MEFV基因最常见变异(n=35, 33.6%), E148Q杂合基因最常见变异(n=16)。4例和2例患者最终被诊断为家族性地中海热(FMF)和高免疫球蛋白D综合征(HIDS),因为他们分别在MEFV和MVK基因中具有确定的双等位基因致病性。结论:包括MEFV和MVK基因在内的基因面板可能对临床类似PFAPA的患者有用,因为他们可能患有HIDS或FMF,但缺乏确切疾病的典型特征。尽管如此,我们认为应该为不同的人群开发不同的遗传小组。
{"title":"Utility of a targeted next-generation sequencing-based genetic screening panel in patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome.","authors":"Rabia Miray Kışla Ekinci,&nbsp;Özlem Anlaş,&nbsp;Özge Özalp","doi":"10.46497/ArchRheumatol.2023.9681","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9681","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to investigate a genetic panel in patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome and examine its performance for an accurate differential diagnosis.</p><p><strong>Patients and methods: </strong>Between January 2021 and January 2022, a total of 104 children with PFAPA syndrome (63 males, 41 females; mean age: 4.8±2.3 years; range, 1.2 to 8.9 years) were retrospectively analyzed. Next-generation sequencing test was performed using a custom QIAGEN- QIAseq™ Targeted DNA Panel which includes six genes namely <i>ELANE, LPIN2, MEFV, MVK, NLRP3</i>, and <i>TNFRSF1A</i>.</p><p><strong>Results: </strong>Of 104 patients, 38 (36.5%) had variants in the genetic panel. The most common variants were found in the <i>MEFV</i> gene (n=35, 33.6%), the most frequent genotype was E148Q heterozygosity (n=16). Four and two patients were eventually diagnosed with Familial Mediterranean fever (FMF) and hyperimmunoglobulin D syndrome (HIDS), since they had confirmative biallelic pathogenic in the <i>MEFV</i> and <i>MVK</i> genes, respectively.</p><p><strong>Conclusion: </strong>A genetic panel, including <i>MEFV</i> and <i>MVK</i> genes, may be useful in patients, clinically resembling PFAPA, since they may have HIDS or FMF, but lack typical features of the exact disease. Nonetheless, we believe that distinct genetic panels should be developed for different populations.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/8e/ArchRheumatol-2023-38-299.PMC10481688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10190500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hearing loss can also be seen in patients with nonradiographic axial spondyloarthropathies as well as radiographic axial spondyloarthropathies. 听力损失也可以在非影像学诊断的中轴性椎体关节病和影像学诊断的中轴性椎体关节病患者中看到。
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.10186
Hanife Çağlar Yağcı, İlker Yağcı, Osman İlkay Özdamar, Cansu Tosyalı Salman, Özlem Ertuğrul

Objectives: Hearing loss has been described in patients with radiographic axial spondyloarthropathies (R-AxSpA) but has not been studied in patients with non-radiographic axial spondyloarthropathies (NR-AxSpA); accordingly, the aim of the study was to compare hearing loss in patients with NR-AxSpA, R-AxSpA, and healthy individuals.

Patients and methods: This cross-sectional observational study was conducted with 68 participants (30 males, 38 females; mean age: 39.8±7.4 years) between March 2021 and March 2022. Of the participants, 16 were patients with NR-AxSpA, 15 were patients with R-AxSpA, and 37 were healthy controls. Disease activity and radiological and audiological features were analyzed. The audiological assessment included pure-tone audiometric tests at octave frequencies of 250 to 8000 Hz and transient evoked otoacoustic emissions.

Results: Hearing loss was found in three (8%) in the healthy group, five (31.3%) in the NR-AxSpA group, and 10 (66.7%) in the R-AxSpA group. The chi-square analysis showed a statistical significance (p=0.001). Values of audiometric tests yielded significant differences between the control and R-AxSpA group and also the control and NR-AxSpA group. For the air conduction studies, the statistical significance began at 1000 Hz in the R-AxSpA group. It was found that in the NR-AxSpA group, the statistical difference started in higher frequencies. The bone conduction audiometric studies were similar to air conduction studies. Transient evoked otoacoustic emission studies showed that the R-AxSpA group was significantly affected compared to the control and NR-AxSpA groups. There was no statistical difference between the control and NR-AxSpA groups.

Conclusion: Both NR-AxSpA and R-AxSpA patients had hearing loss; however, in pure-tone audiometric tests, the abnormalities began in lower frequencies in the R-AxSpA group than in the NR-AxSpA group.

目的:影像学诊断的中轴性椎关节病(R-AxSpA)患者有听力损失,但未对非影像学诊断的中轴性椎关节病(NR-AxSpA)患者进行研究;因此,本研究的目的是比较NR-AxSpA患者、R-AxSpA患者和健康个体的听力损失。患者和方法:本横断面观察性研究共有68名参与者(30名男性,38名女性;平均年龄:39.8±7.4岁(2021年3月至2022年3月)。在参与者中,16名是NR-AxSpA患者,15名是R-AxSpA患者,37名是健康对照。分析疾病活动度、放射学和听力学特征。听力学评估包括250 ~ 8000hz的纯音听力学测试和瞬态诱发耳声发射。结果:健康组听力损失3例(8%),NR-AxSpA组听力损失5例(31.3%),R-AxSpA组听力损失10例(66.7%)。卡方分析显示差异有统计学意义(p=0.001)。听力测试值在对照组和R-AxSpA组之间以及对照组和NR-AxSpA组之间存在显著差异。对于空气传导研究,R-AxSpA组的统计显著性开始于1000 Hz。结果发现,在NR-AxSpA组中,统计差异从更高的频率开始。骨传导听力学研究与空气传导研究相似。瞬态诱发耳声发射研究表明,与对照组和NR-AxSpA组相比,R-AxSpA组受到显著影响。对照组与NR-AxSpA组间无统计学差异。结论:NR-AxSpA和R-AxSpA患者均存在听力损失;然而,在纯音听力测试中,R-AxSpA组的异常开始频率低于NR-AxSpA组。
{"title":"Hearing loss can also be seen in patients with nonradiographic axial spondyloarthropathies as well as radiographic axial spondyloarthropathies.","authors":"Hanife Çağlar Yağcı,&nbsp;İlker Yağcı,&nbsp;Osman İlkay Özdamar,&nbsp;Cansu Tosyalı Salman,&nbsp;Özlem Ertuğrul","doi":"10.46497/ArchRheumatol.2023.10186","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.10186","url":null,"abstract":"<p><strong>Objectives: </strong>Hearing loss has been described in patients with radiographic axial spondyloarthropathies (R-AxSpA) but has not been studied in patients with non-radiographic axial spondyloarthropathies (NR-AxSpA); accordingly, the aim of the study was to compare hearing loss in patients with NR-AxSpA, R-AxSpA, and healthy individuals.</p><p><strong>Patients and methods: </strong>This cross-sectional observational study was conducted with 68 participants (30 males, 38 females; mean age: 39.8±7.4 years) between March 2021 and March 2022. Of the participants, 16 were patients with NR-AxSpA, 15 were patients with R-AxSpA, and 37 were healthy controls. Disease activity and radiological and audiological features were analyzed. The audiological assessment included pure-tone audiometric tests at octave frequencies of 250 to 8000 Hz and transient evoked otoacoustic emissions.</p><p><strong>Results: </strong>Hearing loss was found in three (8%) in the healthy group, five (31.3%) in the NR-AxSpA group, and 10 (66.7%) in the R-AxSpA group. The chi-square analysis showed a statistical significance (p=0.001). Values of audiometric tests yielded significant differences between the control and R-AxSpA group and also the control and NR-AxSpA group. For the air conduction studies, the statistical significance began at 1000 Hz in the R-AxSpA group. It was found that in the NR-AxSpA group, the statistical difference started in higher frequencies. The bone conduction audiometric studies were similar to air conduction studies. Transient evoked otoacoustic emission studies showed that the R-AxSpA group was significantly affected compared to the control and NR-AxSpA groups. There was no statistical difference between the control and NR-AxSpA groups.</p><p><strong>Conclusion: </strong>Both NR-AxSpA and R-AxSpA patients had hearing loss; however, in pure-tone audiometric tests, the abnormalities began in lower frequencies in the R-AxSpA group than in the NR-AxSpA group.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/44/ArchRheumatol-2023-38-257.PMC10481684.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis. COVID-19对青少年系统性硬化症患者临床病程及治疗的影响
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9636
Amra Adrovic, Mehmet Yıldız, Fatih Haşlak, Sezgin Şahin, Oya Köker, Aybüke Günalp, Kenan Barut, Özgür Kasapçopur

Objectives: This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS).

Patients and methods: Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients' complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021.

Results: Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19.

Conclusion: The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.

目的:探讨严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)大流行对青少年系统性硬化症(JSS)患者的影响。患者与方法:27例患者,其中女性22例,男性5例;平均年龄:20岁;被诊断为JSS并在儿科风湿病科随访的患者(年龄在17至22岁之间)被纳入横断面研究。在2021年1月1日至2021年1月10日期间,开展了一项基于网络的调查,重点关注患者的投诉、获得医疗保健的机会以及对常规治疗的依从性。结果:5例(18.5%)患者病情恶化,6例(22.2%)患者报告在过去6个月内不规律地使用常规硬皮病治疗。自SARS-CoV-2大流行宣布以来,有9例(33.3%)患者未进行常规临床控制。7例(25.9%)患者有家庭接触史。4例(14.8%)患者被诊断为COVID-19,只有1例(3.7%)患者住院。9例患者接受生物治疗(托珠单抗);然而,其中只有一人被诊断出患有COVID-19。结论:新冠肺炎疫情对JSS患者的医疗护理影响不明显。远程医疗对于无法来医院的JSS患者来说是一个可接受的选择。
{"title":"The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis.","authors":"Amra Adrovic,&nbsp;Mehmet Yıldız,&nbsp;Fatih Haşlak,&nbsp;Sezgin Şahin,&nbsp;Oya Köker,&nbsp;Aybüke Günalp,&nbsp;Kenan Barut,&nbsp;Özgür Kasapçopur","doi":"10.46497/ArchRheumatol.2023.9636","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9636","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS).</p><p><strong>Patients and methods: </strong>Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients' complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021.</p><p><strong>Results: </strong>Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19.</p><p><strong>Conclusion: </strong>The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/b2/ArchRheumatol-2023-38-267.PMC10481691.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of sleep disturbance and sleep quality in children of mothers with fibromyalgia. 纤维肌痛母亲的孩子睡眠障碍和睡眠质量的决定因素。
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9668
Işıl Fazilet Kartaloğlu, Sevil Karagül, Şule Arslan

Objectives: This study aimed to determine whether maternal diagnosis of Fibromyalgia syndrome (FMS) affects the sleep quality of children.

Patients and methods: This prospective study was conducted with 80 female participants (mean age: 36.2±5.9 years; range 25 to 50 years) and their 80 children (27 males, 53 females; mean age: 6.6±2.6 years; range 2 to 12 years) between August 2019 and November 2020. The FMS group included 40 female FMS patients and their children, whereas the control group consisted of 40 healthy females and their children. In addition to sociodemographic variables, functional status was evaluated by the Fibromyalgia Impact Questionnaire (FIQ), which was completed by mothers with FMS, and the Children's Sleep Habits Questionnaire (CSHQ) was used to evaluate the sleep quality of all children.

Results: There was no statistically significant difference between the two groups in terms of demographic characteristics (p>0.05). The CSHQ score of the two groups was above 41 points and was at a clinically significant level. The median value for the CSHQ score was 60.5 and 52 in the FMS and control groups, respectively. Sleep time, waking up at night, parasomnias, disrupted breathing during sleep, and sleepiness scores were higher in the FMS group than in the control group, and the differences were statistically significant (p<0.001). The delayed falling asleep score, which was reversely coded, was lower in the FMS group than in the control group, and the difference was statistically significant (p<0.001).

Conclusion: This pilot study showed that the children of mothers with high Fibromyalgia Impact Questionnaire scores had sleep disorders. Maternal diagnosis of FMS negatively affects the sleep quality of children.

目的:本研究旨在探讨母亲诊断纤维肌痛综合征(FMS)是否会影响儿童睡眠质量。患者和方法:本前瞻性研究纳入80名女性参与者(平均年龄:36.2±5.9岁;年龄介乎25至50岁)及其80名子女(27名男性,53名女性;平均年龄6.6±2.6岁;2019年8月至2020年11月期间(2至12年)。FMS组包括40名女性FMS患者及其子女,而对照组包括40名健康女性及其子女。除社会人口学变量外,通过纤维肌痛影响问卷(FIQ)评估功能状态,该问卷由FMS母亲完成,并使用儿童睡眠习惯问卷(CSHQ)评估所有儿童的睡眠质量。结果:两组患者人口学特征比较,差异无统计学意义(p>0.05)。两组患者CSHQ评分均在41分以上,均处于临床显著水平。FMS组和对照组的CSHQ得分中位数分别为60.5和52。FMS组的睡眠时间、夜间醒来、睡眠异常、睡眠呼吸中断、困倦评分均高于对照组,差异有统计学意义(p结论:本初步研究表明,纤维肌痛影响问卷得分高的母亲的孩子存在睡眠障碍。母亲诊断为FMS会对儿童睡眠质量产生负面影响。
{"title":"Determinants of sleep disturbance and sleep quality in children of mothers with fibromyalgia.","authors":"Işıl Fazilet Kartaloğlu,&nbsp;Sevil Karagül,&nbsp;Şule Arslan","doi":"10.46497/ArchRheumatol.2023.9668","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9668","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine whether maternal diagnosis of Fibromyalgia syndrome (FMS) affects the sleep quality of children.</p><p><strong>Patients and methods: </strong>This prospective study was conducted with 80 female participants (mean age: 36.2±5.9 years; range 25 to 50 years) and their 80 children (27 males, 53 females; mean age: 6.6±2.6 years; range 2 to 12 years) between August 2019 and November 2020. The FMS group included 40 female FMS patients and their children, whereas the control group consisted of 40 healthy females and their children. In addition to sociodemographic variables, functional status was evaluated by the Fibromyalgia Impact Questionnaire (FIQ), which was completed by mothers with FMS, and the Children's Sleep Habits Questionnaire (CSHQ) was used to evaluate the sleep quality of all children.</p><p><strong>Results: </strong>There was no statistically significant difference between the two groups in terms of demographic characteristics (p>0.05). The CSHQ score of the two groups was above 41 points and was at a clinically significant level. The median value for the CSHQ score was 60.5 and 52 in the FMS and control groups, respectively. Sleep time, waking up at night, parasomnias, disrupted breathing during sleep, and sleepiness scores were higher in the FMS group than in the control group, and the differences were statistically significant (p<0.001). The delayed falling asleep score, which was reversely coded, was lower in the FMS group than in the control group, and the difference was statistically significant (p<0.001).</p><p><strong>Conclusion: </strong>This pilot study showed that the children of mothers with high Fibromyalgia Impact Questionnaire scores had sleep disorders. Maternal diagnosis of FMS negatively affects the sleep quality of children.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/45/ArchRheumatol-2023-38-291.PMC10481693.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of fecal microbial signatures in patients with ankylosing spondylitis. 强直性脊柱炎患者粪便微生物特征的发现。
IF 1.1 4区 医学 Q4 Medicine Pub Date : 2023-06-01 DOI: 10.46497/ArchRheumatol.2023.9124
Yuquan You, Wei Zhang, Meimei Cai, Qingxin Guo, Jiawen Wang, Yaping Cai, Junsheng Lin

Objectives: This study aimed to investigate the characteristics of the gut microbiota in Chinese patients with ankylosing spondylitis (AS) and healthy controls in Quanzhou aiming to explore the correlation between microbiome changes and AS activities.

Patients and methods: In this study, high-throughput sequencing of the gene of 16S ribosomal RNA (16S rRNA) in fecal samples from 40 AS patients and 40 healthy controls, for a total of 80 participants (70 males, 10 females; mean age 33.7±10.7 years; range, 15 to 58 years), was conducted between January 2018 and January 2019. Alpha and beta diversity were analyzed using the QIIME (Quantitative Insights Into Microbial Ecology) software, and differences were analyzed using Student's t-test, linear discriminant analysis coupled with effect size and Metastats. Finally, a correlation network was constructed using Pearson's analysis.

Results: The alpha index values of the AS group were not significantly different from those of the control group. At the genus level, eight genera, Ruminiclostridium_9, Fusicatenibacter, Adlercreutzia, CAG-56, Intestinimonas, Lachnospira, Bacteroides, and Pseudoflavonifractor, were significantly enriched in patients with AS, whereas the abundance of uncultured_bacterium_f_Saccharimonadaceae, Prevotella_7, uncultured_bacterium_f_ Enterobacteriaceae, Cronobacter, Prevotellaceae_NK3B31_group, and Weissella were significantly decreased in patients with AS. In addition, diseaserelated gut microbial communities were detected in patients with AS.

Conclusion: We found differences in the gut microbiome between the patients with AS and controls and identified potential disease activity-related bacterial communities.

目的:本研究旨在调查泉州强直性脊柱炎(AS)患者和健康对照者的肠道微生物群特征,探讨微生物群变化与AS活性的相关性。患者和方法:本研究对40名AS患者和40名健康对照者粪便样本中的16S核糖体RNA (16S rRNA)基因进行了高通量测序,共80名参与者(70名男性,10名女性;平均年龄33.7±10.7岁;年龄范围为15至58岁),于2018年1月至2019年1月期间进行。采用QIIME (Quantitative Insights Into Microbial Ecology)软件分析α和β多样性,采用Student's t检验、线性判别分析、效应大小和亚转移分析分析差异。最后,利用Pearson分析构建相关网络。结果:AS组α指数值与对照组无显著差异。在属水平上,AS患者中Ruminiclostridium_9、Fusicatenibacter、Adlercreutzia、CAG-56、testinimonas、Lachnospira、Bacteroides和pseudo黄酮因子8个属的丰度显著富集,而未培养的bacterium_f_saccharimonadaceae、Prevotella_7、未培养的bacteri_f_enterobacteriaceae、Cronobacter、Prevotellaceae_NK3B31_group和Weissella的丰度显著降低。此外,在AS患者中检测到与疾病相关的肠道微生物群落。结论:我们发现AS患者和对照组之间的肠道微生物组存在差异,并确定了潜在的疾病活动相关细菌群落。
{"title":"Discovery of fecal microbial signatures in patients with ankylosing spondylitis.","authors":"Yuquan You,&nbsp;Wei Zhang,&nbsp;Meimei Cai,&nbsp;Qingxin Guo,&nbsp;Jiawen Wang,&nbsp;Yaping Cai,&nbsp;Junsheng Lin","doi":"10.46497/ArchRheumatol.2023.9124","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9124","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the characteristics of the gut microbiota in Chinese patients with ankylosing spondylitis (AS) and healthy controls in Quanzhou aiming to explore the correlation between microbiome changes and AS activities.</p><p><strong>Patients and methods: </strong>In this study, high-throughput sequencing of the gene of 16S ribosomal RNA (16S rRNA) in fecal samples from 40 AS patients and 40 healthy controls, for a total of 80 participants (70 males, 10 females; mean age 33.7±10.7 years; range, 15 to 58 years), was conducted between January 2018 and January 2019. Alpha and beta diversity were analyzed using the QIIME (Quantitative Insights Into Microbial Ecology) software, and differences were analyzed using Student's t-test, linear discriminant analysis coupled with effect size and Metastats. Finally, a correlation network was constructed using Pearson's analysis.</p><p><strong>Results: </strong>The alpha index values of the AS group were not significantly different from those of the control group. At the genus level, eight genera, <i>Ruminiclostridium_9, Fusicatenibacter, Adlercreutzia, CAG-56, Intestinimonas, Lachnospira, Bacteroides</i>, and <i>Pseudoflavonifractor</i>, were significantly enriched in patients with AS, whereas the abundance of <i>uncultured_bacterium_f_Saccharimonadaceae, Prevotella_7, uncultured_bacterium_f_ Enterobacteriaceae, Cronobacter, Prevotellaceae_NK3B31_group</i>, and <i>Weissella</i> were significantly decreased in patients with AS. In addition, diseaserelated gut microbial communities were detected in patients with AS.</p><p><strong>Conclusion: </strong>We found differences in the gut microbiome between the patients with AS and controls and identified potential disease activity-related bacterial communities.</p>","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/69/ArchRheumatol-2023-38-217.PMC10481682.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10192501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archives of rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1